Dosing & Titration | ENTRESTO® (sacubitril/valsartan)

Start ENTRESTO^® with confidence

ENTRESTO film-coated tablets are available in 3 dosage strengths¹

Low starting dose: 24/26 mg BID. Recommended starting dose: 49/51 mg BID. Target dose: 97/103 mg BID.

How to prescribe ENTRESTO to your adult patients

Choose initial dose of ENTRESTO based on current treatment and titrate to the target dose¹

SWITCHING FROM A LOWER DOSE OR NOT CURRENTLY ON AN ACEi OR ARB¹:

SWITCHING FROM A HIGHER DOSE OF AN ACEi OR ARB¹:

ENTRESTO is contraindicated with concomitant use of an ACEi and in patients with a history of angioedema related to previous ACEi or ARB therapy¹
Avoid use of ENTRESTO with an ARB, because ENTRESTO contains the angiotensin II receptor blocker valsartan¹

Unless your patient is on a high ACEi/ARB dose, start ENTRESTO at 24/26 mg twice daily and double the dose every 2 to 4 weeks, as tolerated by the patient. When switching from an ACEi, be sure to allow for a 36-hour washout period prior to initiating ENTRESTO.¹

DOSING IN PATIENTS WITH RENAL OR HEPATIC IMPAIRMENT

ENTRESTO SPRINKLE film-coated oral pellets within capsules are available in 2 dosage strengths¹

ENTRESTO SPRINKLES

Two capsules containing film coated oral pellets. One with a white end and a dose of 6mg/6mg, the other with an orange end and a dose of 15mg/16mg.

For complete dosing and administration information, please refer to the full Prescribing Information, including Instructions for Use

Click here for Instructions for Use

*In PARAGON-HF, defined as LVEF ≥45% with structural heart disease (LAE or LVH); median LVEF was 57%. LVEF is a variable measure and the normal range can vary.¹

Start ENTRESTO^® with confidence

ENTRESTO film-coated tablets are available in 3 dosage strengths¹

How to prescribe ENTRESTO to your adult patients

SWITCHING FROM A LOWER DOSE OR NOT CURRENTLY ON AN ACEi OR ARB¹:

SWITCHING FROM A HIGHER DOSE OF AN ACEi OR ARB¹:

DOSING IN PATIENTS WITH RENAL OR HEPATIC IMPAIRMENT

How to prescribe ENTRESTO for severe renal impairment (eGFR <30 mL/min/1.73 m²) or moderate hepatic impairment (Child-Pugh B classification)¹

ENTRESTO SPRINKLE film-coated oral pellets within capsules are available in 2 dosage strengths¹

ENTRESTO SPRINKLES

Discover support and resources to help your patients start on ENTRESTO

See the clinical trial timeline of ENTRESTO

Learn about the dual mechanism of action of ENTRESTO

Important Safety Information

Indication

Definitions & References

Start ENTRESTO® with confidence

ENTRESTO film-coated tablets are available in 3 dosage strengths1

How to prescribe ENTRESTO to your adult patients

SWITCHING FROM A LOWER DOSE OR NOT CURRENTLY ON AN ACEi OR ARB1:

SWITCHING FROM A HIGHER DOSE OF AN ACEi OR ARB1:

DOSING IN PATIENTS WITH RENAL OR HEPATIC IMPAIRMENT

ENTRESTO SPRINKLE film-coated oral pellets within capsules are available in 2 dosage strengths1

ENTRESTO SPRINKLES

Discover support and resources to help your patients start on ENTRESTO

See the clinical trial timeline of ENTRESTO

Learn about the dual mechanism of action of ENTRESTO

Definitions & References

Start ENTRESTO^® with confidence

ENTRESTO film-coated tablets are available in 3 dosage strengths¹

SWITCHING FROM A LOWER DOSE OR NOT CURRENTLY ON AN ACEi OR ARB¹:

SWITCHING FROM A HIGHER DOSE OF AN ACEi OR ARB¹:

ENTRESTO SPRINKLE film-coated oral pellets within capsules are available in 2 dosage strengths¹